Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment

Journal of Nanobiotechnology

Raquel Juárez-Sánchez¹  Maria Ángeles Muñoz-Fernández¹  Ignacio Relaño-Rodríguez²  Eduardo Muñoz³  Carolina Pavicic⁴ 

[1] 0000 0001 0277 7938, grid.410526.4, Molecular Immunology Laboratory, Hospital General Universitario Gregorio Marañón, Madrid, Spain;Health Research Institute Gregorio Marañón (IiSGM), Spanish HIV HGM BioBank, Madrid, Spain;Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain;0000 0001 0277 7938, grid.410526.4, Molecular Immunology Laboratory, Hospital General Universitario Gregorio Marañón, Madrid, Spain;Health Research Institute Gregorio Marañón (IiSGM), Spanish HIV HGM BioBank, Madrid, Spain;Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain;Innohealth, Parque Científico de Madrid, Madrid, Spain;0000 0001 2183 9102, grid.411901.c, Department of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigaciones Biomédicas de Córdoba (IMIBIC)/Reina Sofia University Hospital University of Córdoba, Córdoba, Spain;Innohealth, Parque Científico de Madrid, Madrid, Spain;

关键词: Nanomedicine;    Dendrimers;    HIV-1 latency;    Latency reversal agents;   

DOI  :  10.1186/s12951-019-0500-4

来源: publisher

【 摘 要 】

BackgroundThe major obstacle impeding human immunodeficiency virus-1 (HIV-1) eradication in antiretroviral treatment (ART) treated HIV-1 subjects is the establishment of long-lived latently infected resting CD4+ T cells. Due to the fact that no drug has been effective, the search for new drugs and combinations are a priority in the HIV cure. Treatments based on nanotechnology have emerged as an innovative and promising alternative to current and conventional therapies. In this respect, nanotechnology opens up a new door for eliminating latent HIV infection. We studied the role of G1-S4, G2-S16 and G3-S16 polyanionic carbosilane dendrimers in the context of latent HIV-1 persistence. Moreover, we study the efficiency of these dendrimers in combination with latency reversal agents (LRAs) against HIV-1 infection.MethodsJ89GFP lymphocyte and THP89GFP monocyte derived cell lines latently infected with HIV-1 p89GFP were used as an in vitro model of latency for our study. Viability assays by 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) were performed to determine the working concentrations of dendrimers and LRAs. Both cell lines were treated with G1-S4, G2-S16 and G3-S16 either alone or in combination with bryostatin (BRY), romidepsin (RMD) or panobinostat (PNB) for 24 and 48 h. The expression pattern of GFP was measured by flow cytometry and referred as measure of viral reactivation.Results and discussionThe combination treatment of the dendrimers with the protein kinase C (PKC) agonist did not modify the antilatency activity in J89GFP lymphocyte cell line. Interestingly enough, G3-S16 dendrimer alone and its combination with BRY, RMD or PNB showed a significant increased expression of GFP in the THP89GFP monocyte cell line.ConclusionWe showed for the first time that nanoparticles, in this case, G3-S16 anionic carbosilan dendrimer may play an important role in new treatments against HIV-1 infection.

【 授权许可】

CC BY